Bisphosphonate-related osteonecrosis of the jaws - Characteristics, risk factors, clinical features, localization and impact on oncological treatment

被引:172
|
作者
Otto, Sven [1 ]
Schreyer, Christian [1 ]
Hafner, Sigurd [1 ]
Mast, Gerson [1 ]
Ehrenfeld, Michael [1 ]
Stuerzenbaum, Stephen [2 ]
Pautke, Christoph [1 ]
机构
[1] Univ Munich, Dept Oral & Maxillofacial Surg, D-80337 Munich, Germany
[2] Kings Coll London, Analyt & Environm Sci Div, London SE1 9NH, England
基金
英国医学研究理事会;
关键词
Osteonecrosis of the jaw; Bisphosphonates; ONJ; BRONJ; Risk factors; Clinical features; Localization; PREVENTIVE MEASURES; MULTIPLE-MYELOMA; ZOLEDRONIC ACID; CANCER; BONE; IMPLEMENTATION; PAMIDRONATE; ALENDRONATE;
D O I
10.1016/j.jcms.2011.05.003
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Introduction: Osteonecrosis of the jaw (ONJ) is a serious side-effect of intravenous nitrogen-containing bisphosphonate therapy frequently used in the treatment of malignant diseases. Despite numerous case series published so far studies with detailed investigations into risk factors, the precise localization of ONJ and impact of ONJ on the oncological treatment remain sparse. Patients and methods: This single-centre study collated medical records (2003-2009) of all patients that suffered from ONJ within the Department of Oral and Maxillofacial Surgery, Ludwig-Maximilians-University of Munich, Germany. In total, 126 patients fulfilled the case criteria of ONJ and were examined clinically. The complete medical history including detailed questionnaires was collected of 66 patients, focussing in particular on the identification of underlying risk factors, clinical features, ONJ localization as well as the impact on the oncological treatment. Results: The majority of ONJ cases occurred in patients suffering from malignant diseases (n = 117; 92.8%), in particular breast cancer (n = 57; 45.2%), multiple myeloma (n = 37; 29.4%) and prostate cancer (n = 13; 10.3%), all received nitrogen-containing bisphosphonates intravenously. ONJ was also diagnosed in 9 patients (7.1%) suffering from osteoporosis or rheumatoid arthritis. The most prevalent clinical feature was exposed necrotic bone (93.9%) in the oral cavity which was accompanied in 78.8% of cases by pain. A predilection for the mandible and in particular for molar and premolar regions in both jaws was shown. Although no recommendation concerning the oncologic treatment was made, the manifestation of ONJ resulted (in a significant proportion of the patients) in a change of medication and schedule. The most frequent co-medications were steroids and anti-angiogenetic drugs, such as thalidomide. Discussion: The predilection for mandibular molar and premolar regions, and the infectious conditions that often precede the onset of ONJ support recent pathogenesis theories stating that local inflammation and associated pH-changes may trigger the release and activation of nitrogen-containing bisphosphonates ultimately resulting in necrosis. Conclusion: The development of ONJ has a multi-factorial aetiology and the clinical presentation can vary markedly. ONJ cannot only impair the quality of life but also the treatment of the underlying disease. (C) 2011 European Association for Cranio-Maxillo-Facial Surgery.
引用
收藏
页码:303 / 309
页数:7
相关论文
共 50 条
  • [1] RISK FACTORS FOR BISPHOSPHONATE-RELATED OSTEONECROSIS OF THE JAWS
    Fleisher, Kenneth E.
    Glickman, Robert S.
    JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2011, 69 (04) : 959 - 959
  • [2] RISK FACTORS FOR BISPHOSPHONATE-RELATED OSTEONECROSIS OF THE JAWS
    Kyrgidis, Athanassios
    Vahtslvanos, Konstantinos
    JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2009, 67 (11) : 2553 - 2554
  • [3] Factors influencing surgical treatment of bisphosphonate-related osteonecrosis of the jaws
    Wutzl, Arno
    Pohl, Sebastian
    Sulzbacher, Irene
    Seemann, Rudolf
    Lauer, Guenter
    Ewers, Rolf
    Drach, Johannes
    Klug, Clemens
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2012, 34 (02): : 194 - 200
  • [4] Treatment results of bisphosphonate-related osteonecrosis of the jaws
    Wutzl, Arno
    Biedermann, Edwin
    Wanschitz, Felix
    Seemann, Rudolf
    Klug, Clemens
    Baumann, Arnulf
    Watzinger, Franz
    Schicho, Kurt
    Ewers, Rolf
    Millesi, Gabriele
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2008, 30 (09): : 1224 - 1230
  • [5] Clinical study of diagnosis and treatment of bisphosphonate-related osteonecrosis of the jaws
    Kim, Kyung-Wook
    Kim, Beom-Jin
    Lee, Chung-Hyun
    JOURNAL OF THE KOREAN ASSOCIATION OF ORAL AND MAXILLOFACIAL SURGEONS, 2011, 37 (01) : 54 - 61
  • [6] Bisphosphonate-related osteonecrosis of the jaws
    Passeri, Luis Augusto
    Bertolo, Manoel Barros
    Abuabara, Allan
    REVISTA BRASILEIRA DE REUMATOLOGIA, 2011, 51 (04) : 401 - 407
  • [7] Bisphosphonate-related osteonecrosis of the jaws
    Kushner, George M.
    Alpert, Brian
    CURRENT OPINION IN OTOLARYNGOLOGY & HEAD AND NECK SURGERY, 2011, 19 (04): : 302 - 306
  • [8] TREATMENT PROTOCOLS OF BISPHOSPHONATE-RELATED OSTEONECROSIS OF THE JAWS
    Kyrgidis, Athanassios
    Koloutsos, Georgios
    Vahtsevanos, Konstantinos
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2009, 31 (08): : 1112 - 1113
  • [9] Bisphosphonate-related osteonecrosis of the jaws - A review
    Kuehl, Sebastian
    Walter, Christian
    Acham, Stephan
    Pfeffer, Roland
    Lambrecht, J. Thomas
    ORAL ONCOLOGY, 2012, 48 (10) : 938 - 947
  • [10] Clinical and Image Findings in Bisphosphonate-Related Osteonecrosis of the Jaws
    Farias, Diogo Silva
    Zen Filho, Edson Virgilio
    Leitao de Oliveira, Thais Feitosa
    Tinoco-Araujo, Jose Endrigo
    da Silva Sampieri, Marcelo Bonifacio
    Antunes, Heliton Spindola
    da Silva Santos, Paulo Sergio
    JOURNAL OF CRANIOFACIAL SURGERY, 2013, 24 (04) : 1248 - 1251